Background: Primary and secondary [post-essential thrombocythemia (ET) or polycythemia
vera (PV)] Myelofibrosis (MF) are clonal hematopoietic neoplasms marked by constitutive …

Engraftment and nonrelapse mortality (NRM) after allogeneic hematopoietic cell
transplantation (allo-HCT) depend greatly on the transplantation platform in patients with …

Introduction: The only curative treatment for myelofibrosis (MF) remains allogenic
haematopoietic cell transplantation (allo-HCT) although the risks of non-relapse mortality …

We report the results from a multicenter retrospective study of 69 adult patients who
underwent haploidentical blood or marrow transplantation (haplo-BMT) with post …

Therapeutic management of patients with primary or secondary myelofibrosis (MF) who
experience relapse or graft failure following allogeneic haematopoietic cell transplantation …

Myelofibrosis (MF) is a rare disease responsible for an increasing ineffective hematopoesis
by a progressive fibrosing process in the bone marrow. The only curative treatment option is …

Allogeneic stem cell transplantation (allo-SCT) remains the only potentially curative
treatment for myelofibrosis (MF). 1, 2 The 5-year overall survival (OS) rates in MF patients …

Myelofibrosis (MF) is a chronic progressive hematologic malignancy with a median overall
survival (OS) of approximately 6 years. Allogeneic hematopoietic stem cell transplantation …

Primary or post–essential thrombocythemia/polycythemia vera myelofibrosis is a
Philadelphia-negative myeloproliferative neoplasm with a median survival of approximately …

Allogeneic hematopoietic cell transplantation (HCT) is the only curative option for patients
with myelofibrosis (MF); however, a significant obstacle to proceed to HCT is availability a …